MannKind rallies after global licensing agreement for Afrezza The company and Sanofi (SNY) entered into a worldwide exclusive agreement to develop and commercialize Afrezza Inhalation Powder. The stock is up over 15.5% at time of writing to $9.40, off earlier highs. At that price, next resistance is at $9.63. Support is at $9.29.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.